Handling death as an intercurrent event in time to recovery analysis in COVID-19 treatment clinical trials

por Li, Hong, Gleason, Kevin J., Hu, Yiran, Lovell, Sandra S., Mukhopadhyay, Saurabh, Wang, Li, Huang, Bidan
Publicado 2022

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

por Forns, Xavier, Poordad, Fred, Pedrosa, Marcos, Berenguer, Marina, Wedemeyer, Heiner, Ferenci, Peter, Shiffman, Mitchell L., Fried, Michael W., Lovell, Sandra, Trinh, Roger, Lopez‐Talavera, Juan Carlos, Everson, Gregory
Publicado 2015

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection

por Lawitz, Eric J., O'Riordan, William D., Asatryan, Armen, Freilich, Bradley L., Box, Terry D., Overcash, J. Scott, Lovell, Sandra, Ng, Teresa I., Liu, Wei, Campbell, Andrew, Lin, Chih-Wei, Yao, Betty, Kort, Jens
Publicado 2016

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

por Ng, Teresa I., Pilot-Matias, Tami, Tripathi, Rakesh, Schnell, Gretja, Krishnan, Preethi, Reisch, Thomas, Beyer, Jill, Dekhtyar, Tatyana, Irvin, Michelle, Lu, Liangjun, Asatryan, Armen, Campbell, Andrew, Yao, Betty, Lovell, Sandra, Mensa, Federico, Lawitz, Eric J., Kort, Jens, Collins, Christine
Publicado 2018

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

por Poordad, Fred, Felizarta, Franco, Asatryan, Armen, Sulkowski, Mark S., Reindollar, Robert W., Landis, Charles S., Gordon, Stuart C., Flamm, Steven L., Fried, Michael W., Bernstein, David E., Lin, Chih‐Wei, Liu, Ran, Lovell, Sandra S., Ng, Teresa I., Kort, Jens, Mensa, Federico J.
Publicado 2017

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

por Wyles, David, Poordad, Fred, Wang, Stanley, Alric, Laurent, Felizarta, Franco, Kwo, Paul Y., Maliakkal, Benedict, Agarwal, Kosh, Hassanein, Tarek, Weilert, Frank, Lee, Samuel S., Kort, Jens, Lovell, Sandra S., Liu, Ran, Lin, Chih‐Wei, Pilot‐Matias, Tami, Krishnan, Preethi, Mensa, Federico J.
Publicado 2018

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study

por Jonas, Maureen M., Squires, Robert H., Rhee, Susan M., Lin, Chih‐Wei, Bessho, Kazuhiko, Feiterna‐Sperling, Cornelia, Hierro, Loreto, Kelly, Deirdre, Ling, Simon C., Strokova, Tatiana, del Valle‐Segarra, Antonio, Lovell, Sandra, Liu, Wei, Ng, Teresa I., Porcalla, Ariel, Gonzalez, Yuri Sanchez, Burroughs, Margaret, Sokal, Etienne
Publicado 2019

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence

por Zamor, Philippe J., Brown, Ashley, Dylla, Douglas E., Dillon, John F., Luetkemeyer, Anne F., Feld, Jordan J., Mutimer, David, Ghalib, Reem, Crown, Eric, Lovell, Sandra S., Hu, Yiran, Moreno, Christophe, Nelson, David R., Colombo, Massimo, Papatheodoridis, Georgios, Rockstroh, Juergen K., Skoien, Richard, Lawitz, Eric, Jacobson, Ira M.
Publicado 2021

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

por Flamm, Steven, Mutimer, David, Asatryan, Armen, Wang, Stanley, Rockstroh, Jürgen, Horsmans, Yves, Kwo, Paul Y., Weiland, Ola, Villa, Erica, Heo, Jeong, Gane, Edward, Ryder, Stephen D., Welzel, Tania M., Ruane, Peter J., Agarwal, Kosh, Ng, Teresa I., Xue, Zhenyi, Lovell, Sandra S., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Trinh, Roger, Mensa, Federico J., Wyles, David L.
Publicado 2018